LEO 35299

Drug Profile

LEO 35299

Alternative Names: LEO-35299

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Antipsoriatics
  • Mechanism of Action CXCR4 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 30 Jun 2012 LEO Pharma completes a phase I trial in Psoriasis in France (NCT01580488)
  • 30 Apr 2012 Phase-I clinical trials in Psoriasis in France (Topical)
  • 30 Apr 2012 Phase-I clinical trials in Psoriasis in France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top